ID

29003

Descrizione

A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) given as a booster at 18-24 months of age to pre-term children who have received a three-dose primary immunization course with the same vaccine in study 217744/090.

Keywords

versioni (1)
  1. 20/02/18 20/02/18 -
Titolare del copyright

GlaxoSmithKline (GSK)

Caricato su

20 febbraio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

DTPa-HBV-IPV/Hib vaccine (Infanrix-hexa) Study ID: 101518

Inglese

Visit 1 Eligibility Check

2 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
Descrizione

Compliance of Child

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0008059
A male or female 18-24 months of age at the time of the booster vaccination.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
Subjects must have completed full three-dose primary vaccination course with InfanrixTMhexa in the study 217744/090 (DTPa-HBV-IPV-090).
Descrizione

undefined item

Tipo di dati

text

Written informed consent obtained from the parent or guardian of the subject before study entry.
Descrizione

Informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Free of obvious health problems as established by medical history and clinical examination before entering into the study
Descrizione

Comorbidity, Medical history

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0009488
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the booster vaccination, or planned use during the study period.
Descrizione

other medication during study

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C2347852
Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination since the study conclusion visit of study DTPa-HBV-IPV-090.
Descrizione

Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0121772
UMLS CUI [2]
C0012546
UMLS CUI [3]
C0039614
UMLS CUI [4]
C0043167
UMLS CUI [5]
C0032371
Evidence of previous or intercurrent, diphtheria, tetanus, pertussis hepatitis B, polio and/or Hib disease.
Descrizione

Evidence of previous or intercurrent, diphtheria, tetanus, pertussis hepatitis B, polio and/or Hib disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0121772
UMLS CUI [2]
C0012546
UMLS CUI [3]
C0039614
UMLS CUI [4]
C0043167
UMLS CUI [5]
C0032371
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
Descrizione

immunosuppressive or immunodeficient condition, HIV

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021079
UMLS CUI [2]
C0021051
UMLS CUI [3]
C0019682
Planned administration/ administration of a vaccine not foreseen by the study protocol within the 30 days preceding the booster dose.
Descrizione

other vaccine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2368628
UMLS CUI [1,2]
C1444655
UMLS CUI [1,3]
C2348563
(Planned) administration of immunoglobulins and/or any blood products during the study period starting 3 months before and ending 30 days after the booster vaccination.
Descrizione

immunoglobulins and/or any blood products

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021027
UMLS CUI [2]
C0456388
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
Descrizione

immunosuppressants or other immune-modifying drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0205191
UMLS CUI [2,1]
C0005525
UMLS CUI [2,2]
C0205191
History of seizures (subjects who have had a single, uncomplicated febrile convulsion in the past can be included) or progressive neurological disease.
Descrizione

Seizures or progressive neurological disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0027765
UMLS CUI [1,2]
C1335499
UMLS CUI [2]
C0036572
Major congenital defects or serious chronic illness.
Descrizione

Major congenital defects or serious chronic illness.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0000768
UMLS CUI [1,2]
C0205164
UMLS CUI [2,1]
C0008679
UMLS CUI [2,2]
C0205404
Acute febrile illness (axillary temperature of ! 37.5°) at the time of planned vaccination (warrants deferral of the vaccination pending recovery of the subject).
Descrizione

Acute febrile illness

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0743842
History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
Descrizione

medical history of hypersensitivity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0020517
Any of the following adverse events having occurred after previous administration of DTP vaccine constitute a contraindication to the administration of the vaccine: - Hypersensitivity reaction due to the vaccine. - Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours. - Fever ! 40 °C (axillary temperature) within 48 hours of vaccination. - Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination. - Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
Descrizione

former adverse reactions to DTP vaccine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012559
UMLS CUI [1,2]
C0559546
UMLS CUI [2,1]
C0012559
UMLS CUI [2,2]
C1301624
Ritorna all'inizio della pagina

Similar models

Visit 1 Eligibility Check

2 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI-1)
Compliance of Child
Item
Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
boolean
C1321605 (UMLS CUI [1,1])
C0008059 (UMLS CUI [1,2])
Age
Item
A male or female 18-24 months of age at the time of the booster vaccination.
boolean
C0001779 (UMLS CUI [1])
undefined item
Item
Subjects must have completed full three-dose primary vaccination course with InfanrixTMhexa in the study 217744/090 (DTPa-HBV-IPV-090).
text
Informed consent
Item
Written informed consent obtained from the parent or guardian of the subject before study entry.
boolean
C0021430 (UMLS CUI [1])
Comorbidity, Medical history
Item
Free of obvious health problems as established by medical history and clinical examination before entering into the study
boolean
C0262926 (UMLS CUI [1,1])
C0009488 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI-1)
other medication during study
Item
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the booster vaccination, or planned use during the study period.
boolean
C0013227 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib
Item
Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination since the study conclusion visit of study DTPa-HBV-IPV-090.
boolean
C0121772 (UMLS CUI [1])
C0012546 (UMLS CUI [2])
C0039614 (UMLS CUI [3])
C0043167 (UMLS CUI [4])
C0032371 (UMLS CUI [5])
Evidence of previous or intercurrent, diphtheria, tetanus, pertussis hepatitis B, polio and/or Hib disease
Item
Evidence of previous or intercurrent, diphtheria, tetanus, pertussis hepatitis B, polio and/or Hib disease.
boolean
C0121772 (UMLS CUI [1])
C0012546 (UMLS CUI [2])
C0039614 (UMLS CUI [3])
C0043167 (UMLS CUI [4])
C0032371 (UMLS CUI [5])
immunosuppressive or immunodeficient condition, HIV
Item
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
boolean
C0021079 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
C0019682 (UMLS CUI [3])
other vaccine
Item
Planned administration/ administration of a vaccine not foreseen by the study protocol within the 30 days preceding the booster dose.
boolean
C2368628 (UMLS CUI [1,1])
C1444655 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,3])
immunoglobulins and/or any blood products
Item
(Planned) administration of immunoglobulins and/or any blood products during the study period starting 3 months before and ending 30 days after the booster vaccination.
boolean
C0021027 (UMLS CUI [1])
C0456388 (UMLS CUI [2])
immunosuppressants or other immune-modifying drugs
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0005525 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
Seizures or progressive neurological disease
Item
History of seizures (subjects who have had a single, uncomplicated febrile convulsion in the past can be included) or progressive neurological disease.
boolean
C0027765 (UMLS CUI [1,1])
C1335499 (UMLS CUI [1,2])
C0036572 (UMLS CUI [2])
Major congenital defects or serious chronic illness.
Item
Major congenital defects or serious chronic illness.
boolean
C0000768 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0008679 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Acute febrile illness
Item
Acute febrile illness (axillary temperature of ! 37.5°) at the time of planned vaccination (warrants deferral of the vaccination pending recovery of the subject).
boolean
C0743842 (UMLS CUI [1])
medical history of hypersensitivity
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
boolean
C0262926 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
former adverse reactions to DTP vaccine
Item
Any of the following adverse events having occurred after previous administration of DTP vaccine constitute a contraindication to the administration of the vaccine: - Hypersensitivity reaction due to the vaccine. - Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours. - Fever ! 40 °C (axillary temperature) within 48 hours of vaccination. - Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination. - Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
boolean
C0012559 (UMLS CUI [1,1])
C0559546 (UMLS CUI [1,2])
C0012559 (UMLS CUI [2,1])
C1301624 (UMLS CUI [2,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial